← Back

Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A

Shanghai Aohua Photoelectricity Endoscope Co., Ltd. researches, develops, manufactures, and sells electronic endoscope equipment and endoscopic diagnosis and treatment consumables in China and internationally. Its products include electronic digestive endoscopes, otolaryngoscopes, bronchoscopes, and endoscopic diagnostic and treatment consumables used in respiratory medicine, general surgery, otolaryngology, orthopedics, urology, gynecology, gastroenterology, and emergency medicine. The company was founded in 1994 and is based in Shanghai, China.

Country
Price · split & dividend adjusted
News & notes moving 688212.CG
688212.CG▼

Aohua Endoscopy posts net loss of 85.6196 million yuan in 2026 interim report, widening year on year

Aohua Endoscopy released its 2026 interim report, with net profit attributable to the parent company at a loss of 85.6196 million yuan, an increase in loss of 44.8544 million yuan compared with the same period last year. The company's total operating revenue was 280 million yuan, up 7.37 percent year on year. Net cash outflow from operating activities was 83.531 million yuan, narrowing for the second consecutive year. The company's latest gross margin was 63.86 percent, down 7.77 percentage points from the previous quarter and up 1.47 percentage points from the same period last year. Its latest return on equity was negative 7.00 percent, down 3.77 percentage points from the same period last year. Diluted earnings per share were negative 0.64 yuan, a decrease of 0.34 yuan from the same period last year.
688212.CG · Capital · Negative Net loss widened to 85.62 million yuan in interim report
Read original ↗
Jiemian·45dRead more →
China
Brain-Computer Interface▲

Zhejiang Issues Brain-Computer Interface Measures, Biolight Surges by 20% in Afternoon Trading

The medical device sector rebounded in afternoon trading, with Biolight hitting the 20% daily limit up. Earlier, Chaoyan Medical rose by the daily limit, Aohua Endoscopy gained over 10%, and Apon Medical, Rendu Biotechnology, Haitex, Nanwei Medical, and Lude Medical also followed the upward trend. The General Office of the Zhejiang Provincial People's Government issued several measures this morning to promote industry-academia-research collaboration in brain-computer interfaces, aiming for future industry revenue from brain-computer interfaces to exceed 5 billion yuan by 2027, and to establish a globally competitive hub for brain-computer interface technology and industry innovation by 2030.
About megatrends
Brain-Computer Interface › Non-invasive BCI & Neurotech ▲Regulation
300246.CS · Regulation · Positive Zhejiang's BCI measures boost sector, Biolight surges 20%.
688193.CG · Regulation · Positive BCI policy measures lift medical device sector, Rendu follows uptrend.
688212.CG · Regulation · Positive BCI policy measures lift medical device sector, Aohua gains over 10%.
300753.CS · Regulation · Positive BCI policy measures lift medical device sector, Apon follows uptrend.
江苏鹿得医疗电子股份有限公司 · Regulation · Positive BCI policy measures lift medical device sector, Lude follows uptrend.
Read original ↗
上海证券报·53dRead more →